产品
编 号：F462208
分子式：C17H18F3N3O3
分子量：369.34
分子式：C17H18F3N3O3
分子量：369.34
产品类型
规格
价格
是否有货
500mg
320
In-stock
1g
512
In-stock
5g
询价
询价
10g
询价
询价
结构图
CAS No: 79660-72-3
产品详情
生物活性：
Fleroxacin (RO 23-6240) is a broad-spectrum antimicrobial fluoroquinolone.
体内研究：
Fleroxacin (Ro 23-6240) is a new trifluorinated quinolone exhibiting high activity against a broad spectrum of gram-negative and gram-positive bacteria. Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e.g., maximum concentration of 2.3 micrograms/ml after an oral dose of 200 mg). Fleroxacin (Ro 23-6240) is effective against Haemophilus ducreyi in vitro. Fleroxacin (Ro 23-6240), 200 or 400 mg as a single oral dose, is efficacious therapy for microbiologically proven chancroid in patients who do not have concurrent HIV-1 infection. Among HIV-1-infected men, a single dose of 200 or 400 mg of fleroxacin is inadequate therapy for chancroid.
Fleroxacin (RO 23-6240) is a broad-spectrum antimicrobial fluoroquinolone.
体内研究：
Fleroxacin (Ro 23-6240) is a new trifluorinated quinolone exhibiting high activity against a broad spectrum of gram-negative and gram-positive bacteria. Fleroxacin is characterized pharmacokinetically by a long elimination half-life (9 to 10 h) and high concentrations in plasma (e.g., maximum concentration of 2.3 micrograms/ml after an oral dose of 200 mg). Fleroxacin (Ro 23-6240) is effective against Haemophilus ducreyi in vitro. Fleroxacin (Ro 23-6240), 200 or 400 mg as a single oral dose, is efficacious therapy for microbiologically proven chancroid in patients who do not have concurrent HIV-1 infection. Among HIV-1-infected men, a single dose of 200 or 400 mg of fleroxacin is inadequate therapy for chancroid.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备